Key facts
- It has raised $1.7M across 1 recorded rounds; the latest was Seed Round ($1.7M) in May 2023.
- Notable investors include 1315 Capital, Agent Capital, Minnesota Department of Employment and Economic Development.
- Nu-Tek BioSciences has filed 1 Form D with the SEC, most recently Jun 2023 ($1.7M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Nu-Tek BioSciences
Funding rounds
1 roundsAbout Nu-Tek BioSciences
Developer and manufacturer of peptones and protein hydrolysates intended for a variety of applications in pharmaceuticals and industrial fermentations. The company uses proprietary processes to produce peptones, such as soy peptones, pea peptones, and yeast extracts, which have been proven to increase growth rates and yields, enabling biotech and wellness food industries to manufacture animal-free and allergen-free probiotics.
- Sector
- Healthcare
- HQ
- Minnetonka, MN, United States
- Founded
- 2009
- Employees
- 23
- Website
- nu-tekbiosciences.com/
- Ownership
- Privately Held (backing)
Nu-Tek BioSciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nu-Tek BioSciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nu-Tek BioSciences in its N-PORT filings yet. We sweep new filings monthly.